Neomycin sulfate 50.2 mg (35,000 IU), nystatin 100,000 IU, polymyxin B sulfate 35,000 IU.
Ladipac vaginal capsules contain the following excipients: Hydrogenated and partially hydrogenated soybean oil, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, gelatin, concentrated glycerin.
Local treatment of vaginal and cervico-vaginal infections by bacteria or bacterial combination (especially Candida albicans). Prevention of bacterial infection in some cases eg, before operating lower part of reproductive tract, before parturition, before exploring internal uterus (uterography).
1 vaginal capsule daily in the evening, during 12 days.
Administration: Not for oral purposes. Administer through the vaginal cavity only.
Put deep into the vagina. Stretched position is preferable. In order not to contaminate surroundings, use clean gloves or napkin. Avoid use of internal tampon during treatment. Do not interrupt the treatment during the prescribed period.
History of hypersensitivity to any of the components of Ladipac (or group sensitization).
Treatment duration must be limited due to the danger of selection of resistant microorganisms and the risk of superinfection by these microorganisms.
Topical allergic reaction, especially in long-term treatment.
There is a risk of inactivation when used together with spermicidal agents. Contraceptives.
Store in a room temperature below 30°C.
Shelf-Life: 18 months from manufacturing date.
G01AA51 - nystatin, combinations ; Belongs to the class of antibiotics. Used in the treatment of gynecological infections.